M2 PHARMA-December 19, 2017-GlycoMimetics to Join
NASDAQ Biotechnology Indexdeclared that it has been chosen or inclusion to the
NASDAQ Biotechnology Index.
The
Nasdaq Biotechnology Index is a modified capitalization-weighted index that includes Nasdaq-listed companies classified as either biotechnology or pharmaceutical.
After a year of remarkable gains--accentuated by a near-record number of initial public offerings (IPOs) and 61 percent rise in the
NASDAQ Biotechnology Index (the gain is more than double the S&P 500's 26 percent growth in 2013)--biotech stocks have significantly lost their luster.
According to Evaluate Pharma, the
NASDAQ Biotechnology index grew by 66% in 2013.
The
Nasdaq biotechnology index fell seven per cent for the week.
Biotechnology companies in particular had a standout 2013, with the
Nasdaq Biotechnology Index gaining 66 per cent, topping a 30 per cent increase for the Standard & Poor's 500, and closing on Thursday at a record high of 2,449.
M2 EQUITYBITES-December 24, 2013-Agios Pharmaceuticals announces addition to
Nasdaq Biotechnology IndexThe firm cites the iShares
NASDAQ biotechnology Index, the SPDR S&P Biotech ETF and the First Trust AMEX biotechnology Index ETF, which have all gained over 20% in the past year and outperformed the broader markets by a good margin.
The ETFs seek to provide 200 per cent or -200 per cent of the return of the
NASDAQ Biotechnology Index for a single day.
AVANIR Pharmaceuticals has been selected for addition to the
NASDAQ Biotechnology Index effective Monday, November 20.
